NCT04710641View on ClinicalTrials.gov

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 25, 2025

Study Completion Date

January 25, 2025

Conditions
Hepatocellular CarcinomaHepatitis BHepatitis C
Interventions
DRUG

MTL-CEBPA

Administered once every 3 weeks on Day 1 of each 3 week cycle.

DRUG

Sorafenib

Oral adminstration twice a day

Trial Locations (2)

91012

City of Hope, Duarte

119228

National University Hospital Singapore, Singapore

All Listed Sponsors
lead

Mina Alpha Limited

INDUSTRY

NCT04710641 - Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone | Biotech Hunter | Biotech Hunter